Bone Therapeutics Notice of Full Year 2018 Results

 

BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, will announce its full year results for the year ended 31 December 2018 on Friday 1 March 2019 at 7am CET.

Thomas Lienard, Chief Executive Officer, and Jean-Luc Vandebroek, Chief Financial Officer, will host a conference call and Q&A at 13:00 CEST / 12:00 BST. The call will be conducted in English and a replay will be available for 30 days via the Company’s website.

To access the conference call, please dial one of the appropriate numbers below quoting the conference ID:

Belgium: +32 (0)800 48 740 or +32 (0)2 400 98 74
France: +33 (0)805 103 028 or +33 (0)1 76 70 07 94
United Kingdom: +44 (0)800 376 7922 or +44 (0)844 571 8892
United States: +1 (866) 966 1396 or +1 (631) 510 7495

Conference ID: 1789228

The presentation will be made available on the Investors section of the Bone Therapeutics website shortly before the call.

To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled start timing.

Note

Bone Therapeutics is a leading cell therapy company addressing high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy products in clinical development across a number of disease areas targeting markets with large unmet medical needs and limited innovation.

Bone Therapeutics’ technology is based on a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells into bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery.

The Company’s primary clinical focus is ALLOB, an allogeneic “off-the-shelf” cell therapy platform derived from stem cells of healthy donors, which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion. In addition, the Company also has JTA-004, a viscosupplement in development for the treatment of knee osteoarthritis.

Bone Therapeutics’ cell therapy products are manufactured to the highest GMP standards and are protected by a rich IP estate covering nine patent families. Further information is available at: www.bonetherapeutics.com.

 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?